Navigation Links
BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
Date:3/5/2013

LYNBROOK, N.Y., March 5, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S., announced today that it will host a conference call and live audio webcast at 4:30 p.m. EDT on Tuesday, March 12, 2013 to report its fourth quarter and full year 2012 financial results and provide a corporate update.

In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com or you may use the link: http://www.videonewswire.com/event.asp?id=92436.

A replay of the call will be available one hour after the end of the conference on March 12, 2013 until 9:00 a.m. EDT on March 27, 2013. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10025434. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Injectable collagenase is currently marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is approved for Dupuytren's contracture in the European Union, Switzerland and Canada. XIAFLEX is also in clinical development for the treatment of several additional promising indications. A supplemental Biologics License Application is currently under standard review at the U.S. Food and Drug Administration for XIAFLEX for the potential treatment of Peyronie's disease. Auxilium is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials. Auxilium is currently partnered with Asahi Kasei Pharma Corporation for the development and commercialization of injectable collagenase for Dupuytren's contracture and Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia, Brazil and Mexico. Pfizer Inc. has marketing rights to XIAPEX® (the EU trade name for XIAFLEX) for Dupuytren's contracture in 46 countries in Eurasia through April 24, 2013.  For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
2. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
3. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
6. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
7. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
8. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
9. Animas Development of a First-Generation Closed Loop Insulin Delivery System Progresses With Data Presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference
10. Medical Equipment Suppliers in Good Health - Research Report on Bruker Corporation, Agilent Technologies Inc., General Electric Company, Becton, Dickinson and Co. and Thermo Fisher Scientific Inc.
11. Medisafe 1 Technologies One-Time Special Dividend Announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2020)... ... February 23, 2020 , ... ... by CARF International, the Commission on Accreditation of Rehabilitation Facilities. CARF International ... is to promote quality, value, and optimal outcomes through continuous improvements under ...
(Date:2/23/2020)... ... February 23, 2020 , ... “Mind, Brain, Body ... the complex interplay between the brain, central nervous system and the body in ... International Association of Eating Disorders Professionals (iaedp™) 2020 Symposium in Orlando, March 26-29 ...
(Date:2/21/2020)... ... February 21, 2020 , ... Nationwide jails are seeing ... Schizophrenia. While someone with a mental illness is no more likely to commit a ... criminal trespass, loitering, or harassment. , They may be experiencing symptoms that lead ...
Breaking Medicine Technology:
(Date:2/28/2020)... LOS ANGELES (PRWEB) , ... February 28, 2020 ... ... behind the liver-boosting shot, Morning Recovery, launches a new product, Liquid Focus ... to help sharpen the mind, provide steady energy, and ease stress. , ...
(Date:2/28/2020)... ... February 27, 2020 , ... ... South Carolina conducting Phase I-IV trials, is excited to announce the screening of ... safety and efficacy of psilocybin for major depressive disorder (MDD). , Dr. Rishi ...
(Date:2/26/2020)... ... 2020 , ... Announcement Key Points: , Hera and Demeetra ... which is best known for its commercialization of the piggyBac® transposase , ... truly dimeric and demonstrates high fidelity with no detectable off-targets while maintaining robust ...
(Date:2/26/2020)... ... February 26, 2020 , ... Nutricare’s PATCH bamboo bandages ... they'll be showcasing their pioneering line of compostable bamboo bandages while competing for one ... Expo West, and we were blown away by the support and interest in green ...
(Date:2/23/2020)... ... February 22, 2020 , ... ... study conducted by Queendom.com reveals that some people who dismiss compliments ... , Analyzing data from 9,568 who took the Emotional Intelligence Test, ...
Breaking Medicine News(10 mins):